OGI vs. PAHC, STOK, NRIX, AUPH, TNGX, LBPH, GHRS, SAGE, LYEL, and ALXO
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Phibro Animal Health (PAHC), Stoke Therapeutics (STOK), Nurix Therapeutics (NRIX), Aurinia Pharmaceuticals (AUPH), Tango Therapeutics (TNGX), Longboard Pharmaceuticals (LBPH), GH Research (GHRS), Sage Therapeutics (SAGE), Lyell Immunopharma (LYEL), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical preparations" industry.
Phibro Animal Health (NASDAQ:PAHC) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
Phibro Animal Health has higher revenue and earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health received 108 more outperform votes than Organigram when rated by MarketBeat users. However, 70.61% of users gave Organigram an outperform vote while only 59.92% of users gave Phibro Animal Health an outperform vote.
Phibro Animal Health has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Phibro Animal Health has a net margin of 1.32% compared to Phibro Animal Health's net margin of -188.38%. Organigram's return on equity of 17.11% beat Phibro Animal Health's return on equity.
99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 34.6% of Organigram shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 0.1% of Organigram shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Phibro Animal Health had 11 more articles in the media than Organigram. MarketBeat recorded 14 mentions for Phibro Animal Health and 3 mentions for Organigram. Phibro Animal Health's average media sentiment score of 1.19 beat Organigram's score of 0.70 indicating that Organigram is being referred to more favorably in the news media.
Phibro Animal Health presently has a consensus price target of $14.75, suggesting a potential downside of 18.24%. Given Organigram's higher possible upside, equities analysts plainly believe Phibro Animal Health is more favorable than Organigram.
Summary
Phibro Animal Health beats Organigram on 12 of the 17 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
